Literature DB >> 26154578

Immunohistochemical Expression of E-Cadherin in Atypical Parathyroid Adenoma.

Ralph Schneider1, Stefanie Bartsch-Herzog, Annette Ramaswamy, Detlef K Bartsch, Elias Karakas.   

Abstract

BACKGROUND: Atypical parathyroid adenoma (APA) is a rare entity, sharing clinical symptoms like solid palpable mass in the neck, laboratory changes with very high serum calcium and parathyroid hormone levels, and some histopathological features with parathyroid carcinomas (PC). However, clinical behavior of APA seems to comply with benign parathyroid tumors (PA). There is some evidence that loss of the membranous staining pattern of E-Cadherin (E-Cad) suggests a key role of epithelial mesenchymal transition in the tumorigenesis of PC. Thus, the aim of this study was to compare clinical and surgical characteristics and immunohistochemical expression of E-Cad in APA, PC, and PA.
METHODS: Data of patients who underwent surgery for primary hyperparathyroidism (pHPT) between 1985 and 2010 were retrospectively evaluated. All data were analyzed with special regard to distinctive criteria of APA, including trabecular growth, broad fibrous bands, nuclear atypia, mitosis, pseudocapsular invasion or strong adherence to the surrounding tissue, and potential invasive growth of a grossly altered and enlarged parathyroid gland. In addition, laboratory and clinical data were evaluated and additional immunohistochemical staining with E-Cad was performed in suspicious APA patients with available tissue.
RESULTS: In 68 patients (39 female, 29 male), the parathyroid tumor was suspicious for APA. In 46 patients, a bilateral cervical exploration was performed. 15 patients underwent an en bloc resection including a hemithyroidectomy and lymphonodular dissection of the ipsilateral central compartment due to the malignant macroscopic aspect of the parathyroid. In seven patients, a focused parathyroid resection was done. The available parathyroid tissue of 38 APA patients was immunopositive for membranous E-Cad staining. During follow-up, only one patient with a successful initial surgery suffered from recurrent pHPT due to another solitary PA 10 years after initial surgery but without evidence of malignancy.
CONCLUSIONS: In contrast to PC, parathyroid tumors suspicious for APA are characterized by a strong membranous E-Cad staining and, like PA, by a benign clinical course.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26154578     DOI: 10.1007/s00268-015-3149-7

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  25 in total

1.  The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression.

Authors:  A Cano; M A Pérez-Moreno; I Rodrigo; A Locascio; M J Blanco; M G del Barrio; F Portillo; M A Nieto
Journal:  Nat Cell Biol       Date:  2000-02       Impact factor: 28.824

2.  Development of a formula to predict parathyroid carcinoma in patients with primary hyperparathyroidism.

Authors:  Elias Karakas; Hans-Helge Müller; Vladimir K Lyadov; Stephanie Luz; Ralph Schneider; Matthias Rothmund; Detlef K Bartsch; Katja Schlosser
Journal:  World J Surg       Date:  2012-11       Impact factor: 3.352

3.  Loss of parafibromin expression in a subset of parathyroid adenomas.

Authors:  C Juhlin; C Larsson; T Yakoleva; I Leibiger; B Leibiger; A Alimov; G Weber; A Höög; A Villablanca
Journal:  Endocr Relat Cancer       Date:  2006-06       Impact factor: 5.678

4.  Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias.

Authors:  Anthony J Gill; Adele Clarkson; Oliver Gimm; Juliane Keil; Henning Dralle; Viive M Howell; Deborah J Marsh
Journal:  Am J Surg Pathol       Date:  2006-09       Impact factor: 6.394

5.  [Parathyroid gland cancer. Problems in diagnosis and therapy].

Authors:  D Bartsch; K P Reimund; C Hasse; W Schwerk; M Rothmund
Journal:  Chirurg       Date:  1993-02       Impact factor: 0.955

Review 6.  Minimal-access/minimally invasive parathyroidectomy for primary hyperparathyroidism.

Authors:  F Fausto Palazzo; Leigh W Delbridge
Journal:  Surg Clin North Am       Date:  2004-06       Impact factor: 2.741

Review 7.  Diagnosis and treatment of patients with parathyroid carcinoma: an update and review.

Authors:  T Obara; Y Fujimoto
Journal:  World J Surg       Date:  1991 Nov-Dec       Impact factor: 3.352

8.  Parathyroid carcinoma: a clinical study of seven cases of functioning and two cases of nonfunctioning parathyroid cancer.

Authors:  K A Aldinger; R C Hickey; M L Ibanez; N A Samaan
Journal:  Cancer       Date:  1982-01-15       Impact factor: 6.860

9.  Clinical course of metastatic parathyroid cancer.

Authors:  K Sandelin; O Tullgren; L O Farnebo
Journal:  World J Surg       Date:  1994 Jul-Aug       Impact factor: 3.352

10.  Natural history of parathyroid carcinoma. Diagnosis, treatment, and results.

Authors:  C A Wang; R D Gaz
Journal:  Am J Surg       Date:  1985-04       Impact factor: 2.565

View more
  3 in total

1.  Using a Novel Diagnostic Nomogram to Differentiate Malignant from Benign Parathyroid Neoplasms.

Authors:  Angelica M Silva-Figueroa; Roland Bassett; Ioannis Christakis; Pablo Moreno; Callisia N Clarke; Naifa L Busaidy; Elizabeth G Grubbs; Jeffrey E Lee; Nancy D Perrier; Michelle D Williams
Journal:  Endocr Pathol       Date:  2019-12       Impact factor: 3.943

Review 2.  Overview of the 2022 WHO Classification of Parathyroid Tumors.

Authors:  Lori A Erickson; Ozgur Mete; C Christofer Juhlin; Aurel Perren; Anthony J Gill
Journal:  Endocr Pathol       Date:  2022-02-17       Impact factor: 3.943

3.  Mathematical model for preoperative differential diagnosis for the parathyroid neoplasms.

Authors:  Julia A Krupinova; Alina R Elfimova; Olga Yu Rebrova; Iya A Voronkova; Anna K Eremkina; Elena V Kovaleva; Irina S Maganeva; Anna M Gorbacheva; Ekaterina E Bibik; Andrey A Deviatkin; Galina A Melnichenko; Natalia G Mokrysheva
Journal:  J Pathol Inform       Date:  2022-08-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.